Key Insights

Highlights

Success Rate

80% trial completion

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 27/100

Termination Rate

12.5%

1 terminated out of 8 trials

Success Rate

80.0%

-6.5% vs benchmark

Late-Stage Pipeline

38%

3 trials in Phase 3/4

Results Transparency

75%

3 of 4 completed with results

Key Signals

3 with results80% success

Data Visualizations

Phase Distribution

8Total

Not Applicable (2)

P 1 (3)

P 3 (1)

P 4 (2)

Trial Status

Completed4

Terminated1

Withdrawn1

Recruiting1

Unknown1

Trial Success Rate

80.0%

Benchmark: 86.5%

Based on 4 completed trials

Clinical Trials (8)

Showing 8 of 8 trials

NCT05586581Phase 1Recruiting

SV2A & TSPO PET Imaging Measures to Reveal Mechanisms of HIV Neuropathogenesis During Antiretroviral Therapy

NCT05571761Not ApplicableWithdrawn

Teleneuropsychological Intervention in Asymptomatic HIV Seropositive Patients: N&C NeuroChange

NCT04015830Not ApplicableCompletedPrimary

Exploring Racial Disparities in Sleep Health and Neurocognitive Function

NCT03081117Phase 1TerminatedPrimary

Intranasal Insulin for the Treatment of HAND

NCT01600170Phase 4CompletedPrimary

Downmodulating Monocyte Activation for HIV-1 Associated Neurocognitive Disorders (HAND)

NCT01263938Phase 4CompletedPrimary

Modulation of Monocyte Activation by Atorvastatin in HIV Infection

NCT01665846Phase 1CompletedPrimary

Ferumoxytol-enhanced Brain MRI in HIV-associated Neurocognitive Disorders

NCT01599975Phase 3UnknownPrimary

A Study Comparing Long-acting Methylphenidate (ConcertaTM) vs. Placebo in the Treatment of Memory Loss Due to HIV

Showing all 8 trials

HIV Dementia